[go: up one dir, main page]

NO20011244L - Behandling av multippelt myelom samt myelom-indusert benresorpsjon ved anvendelse av integrin-antagonister - Google Patents

Behandling av multippelt myelom samt myelom-indusert benresorpsjon ved anvendelse av integrin-antagonister

Info

Publication number
NO20011244L
NO20011244L NO20011244A NO20011244A NO20011244L NO 20011244 L NO20011244 L NO 20011244L NO 20011244 A NO20011244 A NO 20011244A NO 20011244 A NO20011244 A NO 20011244A NO 20011244 L NO20011244 L NO 20011244L
Authority
NO
Norway
Prior art keywords
myeloma
multiple myeloma
treatment
bone resorption
integrin antagonists
Prior art date
Application number
NO20011244A
Other languages
English (en)
Other versions
NO327855B1 (no
NO20011244D0 (no
Inventor
Gregory R Mundy
Toshiyuki Yoneda
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of NO20011244D0 publication Critical patent/NO20011244D0/no
Publication of NO20011244L publication Critical patent/NO20011244L/no
Publication of NO327855B1 publication Critical patent/NO327855B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2836—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD106
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70542—CD106
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Photoreceptors In Electrophotography (AREA)
NO20011244A 1998-09-14 2001-03-12 Anvendelse av integrin-antagonister for fremstilling av et medikament til behandling av multippelt myelom samt myelom-indusert benresorpsjon NO327855B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10018298P 1998-09-14 1998-09-14
PCT/US1999/021170 WO2000015247A2 (en) 1998-09-14 1999-09-13 Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists

Publications (3)

Publication Number Publication Date
NO20011244D0 NO20011244D0 (no) 2001-03-12
NO20011244L true NO20011244L (no) 2001-05-14
NO327855B1 NO327855B1 (no) 2009-10-05

Family

ID=22278506

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20011244A NO327855B1 (no) 1998-09-14 2001-03-12 Anvendelse av integrin-antagonister for fremstilling av et medikament til behandling av multippelt myelom samt myelom-indusert benresorpsjon
NO20011283A NO20011283D0 (no) 1998-09-14 2001-03-14 Anvendelse av integrin-antagonister ved behandling av multippelt myelom og myelom-indusert benresorpsjon

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20011283A NO20011283D0 (no) 1998-09-14 2001-03-14 Anvendelse av integrin-antagonister ved behandling av multippelt myelom og myelom-indusert benresorpsjon

Country Status (28)

Country Link
US (1) US7211252B2 (no)
EP (2) EP2065050A1 (no)
JP (3) JP2002524529A (no)
KR (1) KR100628818B1 (no)
CN (1) CN1236815C (no)
AT (1) ATE418999T1 (no)
AU (1) AU757873B2 (no)
BR (1) BR9913705A (no)
CA (1) CA2343579C (no)
CY (1) CY1109413T1 (no)
CZ (1) CZ302997B6 (no)
DE (1) DE69940206D1 (no)
DK (1) DK1113810T3 (no)
EA (1) EA004270B1 (no)
EE (1) EE05558B1 (no)
ES (1) ES2319831T3 (no)
HU (1) HU229038B1 (no)
IL (2) IL141877A0 (no)
IS (1) IS2631B (no)
NO (2) NO327855B1 (no)
NZ (1) NZ511062A (no)
PL (1) PL203114B1 (no)
PT (1) PT1113810E (no)
SI (1) SI1113810T1 (no)
SK (1) SK287601B6 (no)
TR (1) TR200100734T2 (no)
WO (1) WO2000015247A2 (no)
ZA (1) ZA200102032B (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7618630B2 (en) * 1998-09-14 2009-11-17 Board Of Regents, The University Of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
ES2263485T3 (es) * 1999-09-14 2006-12-16 Biogen Idec Ma Inc. Terapia para insuficiencia renal cronica utilizando uno o mas angtagonistas de integrinas.
US20010046496A1 (en) * 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
AU2002356180A1 (en) * 2001-08-06 2003-03-10 The Regents Of The University Of California Methods for inhibiting angiogenesis
EP2394652A3 (en) * 2004-02-06 2012-10-24 Elan Pharmaceuticals Inc. Methods and compositions for treating tumors and metastatic disease
US8808698B2 (en) * 2006-02-03 2014-08-19 The Regents Of The University Of California Methods for inhibition of lymphangiogenesis and tumor metastasis
EP3042668B1 (en) * 2006-06-07 2018-09-19 The Board of Trustees of the Leland Stanford Junior University Anti-leukocyte recruitment therapy for the treatment of seizures and epilepsy
US20110189206A1 (en) 2008-01-03 2011-08-04 Barbas Iii Carlos F Antibody Targeting Through a Modular Recognition Domain
US8454960B2 (en) 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
US8557243B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
US8557242B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
KR101238061B1 (ko) * 2009-03-31 2013-02-27 한화케미칼 주식회사 Ｖｃａｍ－１에 특이적으로 결합하는 인간 단일클론항체 및 그를 포함하는 염증성 질환 또는 암의 치료용 조성물
EP3202789B1 (en) * 2010-04-16 2020-05-06 Biogen MA Inc. Anti-vla-4 antibodies
WO2012009705A1 (en) 2010-07-15 2012-01-19 Zyngenia, Inc. Ang-2 binding complexes and uses thereof
DK2714738T3 (en) 2011-05-24 2019-01-28 Zyngenia Inc MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS
US20140135483A1 (en) * 2011-06-30 2014-05-15 Gene Techno Science Co., Ltd. Soluble integrin alpha-4 mutant
BR112015023752B1 (pt) 2013-03-15 2023-11-14 Zyngenia, Inc. Domínio de reconhecimento modular (mrd), complexo compreendendo mrd e cetuximabe, usos do complexo para inibir a angiogênese e tratar câncer e composição farmacêutica compreendendo o dito complexo
CN103215223B (zh) * 2013-03-18 2014-10-29 中国人民解放军第四军医大学 人椎间盘髓核细胞和免疫细胞相互作用的体外模型构建方法
CN103838980A (zh) * 2014-03-27 2014-06-04 山东大学 对多发性骨髓瘤骨病治疗方法的疗效进行模拟评测的方法
CN109498799A (zh) * 2016-03-13 2019-03-22 曹帅 一种用于治疗骨髓增生、骨癌的药物组合物及其用途
WO2017205560A1 (en) * 2016-05-27 2017-11-30 Albert Einstein College Of Medicine, Inc. Methods for treating cancer by targeting vcam1 and maea
US11560433B2 (en) 2016-05-27 2023-01-24 Albert Einstein College Of Medicine Methods of treatment by targeting VCAM1 and MAEA
TW202504919A (zh) 2023-05-30 2025-02-01 美商派拉岡醫療公司 α4β7整合素抗體組合物及使用方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ215865A (en) 1985-04-22 1988-10-28 Commw Serum Lab Commission Method of determining the active site of a receptor-binding analogue
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5272263A (en) 1989-04-28 1993-12-21 Biogen, Inc. DNA sequences encoding vascular cell adhesion molecules (VCAMS)
US6307025B1 (en) 1989-04-28 2001-10-23 Biogen, Inc. VCAM fusion proteins and DNA coding therefor
US5217870A (en) 1989-04-28 1993-06-08 Biogen, Inc. Monoclonal antibodies against CDX
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5192746A (en) 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5260277A (en) 1990-09-10 1993-11-09 Tanabe Seiyaku Co., Ltd. Guanidinyl and related cell adhesion modulation compounds
WO1992008464A1 (en) 1990-11-15 1992-05-29 Tanabe Seiyaku Co. Ltd. Substituted urea and related cell adhesion modulation compounds
WO1993008823A1 (en) 1991-11-06 1993-05-13 Tanabe Seiyaku Co., Ltd. Guanidinyl and related cell adhesion modulation compounds
CA2127462C (en) 1992-01-13 1999-03-23 Roy R. Lobb Treatment for asthma
US5871734A (en) 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
US5932214A (en) 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
ES2103468T3 (es) 1992-02-12 1997-09-16 Biogen Inc Tratamiento de la inflamacion intestinal.
AU689454B2 (en) 1992-11-13 1998-04-02 Board Of Regents Of The University Of Washington, The Peripheralization of hematopoietic stem cells
JPH08505628A (ja) 1993-01-08 1996-06-18 田辺製薬株式会社 ペプチド型細胞接着阻害薬
EP0678122B1 (en) 1993-01-12 1999-07-28 Biogen, Inc. Recombinant anti-vla4 antibody molecules
CA2155303C (en) 1993-02-09 2010-04-20 Linda C. Burkly Treatment for insulin dependent diabetes
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
HU220799B1 (hu) * 1994-01-25 2002-05-28 Elan Pharmaceuticals, Inc. Humanizált antitestek VLA-4 leukocita adhéziós molekula ellen
US5510332A (en) * 1994-07-07 1996-04-23 Texas Biotechnology Corporation Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor
DE19541844C1 (de) 1995-11-09 1997-07-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung
US5885786A (en) 1996-04-19 1999-03-23 John Wayne Cancer Institute Methods for screening of substances for inhibition of multidrug resistance
US6692742B1 (en) 1996-06-27 2004-02-17 Chugai Seiyaku Kabushiki Kaisha Remedies for myeloma to be used together with nitrogen mustard antitumor agents
CZ298413B6 (cs) * 1998-05-28 2007-09-26 Biogen Idec Ma Inc. Beta-Alaninový derivát, farmaceutická kompozice tento derivát obsahující a použití tohoto derivátu pro prípravu léciva
US9501219B2 (en) 2012-01-25 2016-11-22 Oracle International Corporation 2D line data cursor
US9713013B2 (en) 2013-03-15 2017-07-18 Elwha Llc Protocols for providing wireless communications connectivity maps
US9400266B2 (en) 2013-03-14 2016-07-26 Rosemount Analytical Inc. Gas chromatograph with improved operation
US9104862B2 (en) 2013-04-01 2015-08-11 Uniquesoft, Llc Secure computing device using new software versions

Also Published As

Publication number Publication date
KR100628818B1 (ko) 2006-09-27
ZA200102032B (en) 2002-11-07
CA2343579C (en) 2012-05-29
US7211252B2 (en) 2007-05-01
IL197686A0 (en) 2011-07-31
JP2002524529A (ja) 2002-08-06
EP1113810A2 (en) 2001-07-11
ES2319831T3 (es) 2009-05-12
US20020022028A1 (en) 2002-02-21
CZ2001916A3 (cs) 2001-08-15
SK6052001A3 (en) 2001-12-03
SI1113810T1 (sl) 2009-04-30
WO2000015247A8 (en) 2009-12-23
NO327855B1 (no) 2009-10-05
ATE418999T1 (de) 2009-01-15
NZ511062A (en) 2003-04-29
IL141877A0 (en) 2002-03-10
PL347128A1 (en) 2002-03-25
PL203114B1 (pl) 2009-08-31
JP5378303B2 (ja) 2013-12-25
EA004270B1 (ru) 2004-02-26
HU229038B1 (hu) 2013-07-29
WO2000015247A2 (en) 2000-03-23
JP2013241441A (ja) 2013-12-05
BR9913705A (pt) 2001-06-05
CZ302997B6 (cs) 2012-02-15
AU6248699A (en) 2000-04-03
AU757873B2 (en) 2003-03-06
HUP0103630A2 (hu) 2002-01-28
EE200100146A (et) 2002-06-17
CY1109413T1 (el) 2014-08-13
CN1321091A (zh) 2001-11-07
CN1236815C (zh) 2006-01-18
TR200100734T2 (tr) 2001-07-23
EP1113810B1 (en) 2008-12-31
CA2343579A1 (en) 2000-03-23
WO2000015247A3 (en) 2000-05-25
NO20011283D0 (no) 2001-03-14
DE69940206D1 (de) 2009-02-12
IS5856A (is) 2001-02-23
KR20010085793A (ko) 2001-09-07
IS2631B (is) 2010-06-15
PT1113810E (pt) 2009-03-10
JP2010235620A (ja) 2010-10-21
HUP0103630A3 (en) 2004-03-01
NO20011244D0 (no) 2001-03-12
DK1113810T3 (da) 2009-04-06
EP2065050A1 (en) 2009-06-03
EA200100362A1 (ru) 2001-12-24
SK287601B6 (sk) 2011-03-04
HK1038313A1 (en) 2002-03-15
EE05558B1 (et) 2012-08-15

Similar Documents

Publication Publication Date Title
NO20011244D0 (no) Behandling av multippelt myelom samt myelom-indusert benresorpsjon ved anvendelse av integrin-antagonister
DE69926639D1 (de) Knochenmarkszellen als quelle von neuronen zur wiederherstellung von gehirn und knochenmark
ATE271393T1 (de) Zusammensetzungen zur erhöhung des hautdurchtritts von arzneistoffen unter verwendung von permeationsbeschleunigern
DE69827424D1 (de) Vorrichtung zur gesteuerten thermischen Behandlung von Gewebe
DE69739303D1 (de) Vorrichtung zur thermischen behandlung von gewebe
DE69738045D1 (de) Verwendung von cetrorelix zur behandlung von benigne prostatahypertrophie und prostatakrebs
DE69937888D1 (de) Verbesserung der herzfunktion durch transplantation mesenchymaler stammzellen
DE69838338D1 (de) Verwendung von antimykotica zur topischen behandlung von pilz-induzierten schleimhautentzündungen
DE69836752D1 (de) Prostaglandinagoniste und deren verwendung zur behandlung von knochenerkrankungen
DE69936890D1 (de) Vorrichtung zur Behandlung von Ischämie
WO2003103581A3 (en) COMPOSITIONS AND METHODS FOR LIVER GROWTH AND PROTECTION
DE59209679D1 (de) Implantat zur elektrischen Impulsbeaufschlagung von lebendem Gewebe
DE69840752D1 (de) Verwendung von coumarine zur behandlung von lebererkrankungen und pankreaserkrankungen
ATE433461T1 (de) Rana pipiens proteine und deren verwendung in der behandlung von tumoren
ATE258062T1 (de) Verwendung von wachstumshormon freisetzenden stoffen und ihren antagonisten zur behandlung von tumoren
DE60027429D1 (de) Dihydrobenzodiazepinen und deren verwendung zur behandlung von dyslipidämien
EP0635263A3 (en) Angiotensin II antagonists (AII) as inhibitors of the growth of adipose tissue.
ATE504309T1 (de) Verwendung von oxytocin zur herstellung einer pharmazeutischen zusammensetzung gegen karzinom in situ und zervizitis
DE19983519T1 (de) Vorrichtung zur Wärmebehandlung von Körpergewebe
EP2236619A3 (en) BCL2L12 polypeptide activators and inhibitors
DE50004024D1 (de) Verwendung von treosulfan zur konditionierung von patienten vor knochenmarktransplantation oder blutstammzelltransplantation
EP1100523A4 (en) TREATMENT OF CENTRAL NERVOUS SYSTEM ISCHEMIA OR TRAUMATISM WITH POLYPEPTIDES OF THE EPIDERMAL GROWTH FACTOR TYPE
DE69907685D1 (de) Verwendung von derivaten von tetrahydropyridinen oder (4-hydroxypiperidin)-butylazolen zur herstellung von präparaten zur schmerzbehandlung
DE59708286D1 (de) Verwendung von wirkstoffmischungen, enthaltend phytostenole und/oder phytostenolester und potenzierungsmittel zur herstellung von hypocholesterinämischen mitteln
NO930932D0 (no) Maksimering av biologiske vekstprosesser ved hjelp av betinget intermodulaer spredning

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees